P38 MAP kinase inhibitors

A compound of formula (I)

• wherein R1 is C1-6 alkyl optionally substituted by a hydroxyl group;
• R2 is H or C1-6 alkyl optionally substituted by a hydroxyl group;
• R3 is H, C1-6 alkyl or C0-3 alkyIC3-6 cycloalkyl,
• Ar is a naphthyl or a phenyl ring either of which may be optionally substituted by one or more groups independently selected from C1-6 alkyl, C1-6 alkoxy, amino, C1-4 mono or di-alkyl amino;
• L is a saturated or unsaturated branched or unbranched C1-8 alkylene chain, wherein one or more carbons are optionally replaced by —O—
• X is 5 or 6 membered heteroaryl group containing at least one nitrogen atom and optionally including 1 or 2 further heteroatoms selected from O, S and N;
• Q is selected from:
• a) a saturated or unsaturated, branched or unbranched C1-10 alkyl chain, wherein at least one carbon is replaced by a heteroatom selected from O, N, S(O)p, wherein said chain is optionally, substituted by one or more groups selected from oxo, halogen, an aryl group, a heteroaryl group or an heterocyclyl group,
• each aryl, heteroaryl or heterocyclyl group bearing 0 to 3 substituents selected from halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, amino, C1-4 mono or di-alkyl amino,
• with the proviso that the atom linked directly to the carbonyl in -NR3C(O)- is not an oxygen or a sulfur atom;
• and
• b) a C0-8 alkyIC5-6 heterocyclyl said heterocyclyl group comprising at least one heteroatom selected from O, N and S, and optionally substituted by one or two or three groups independently selected from halogen C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, amino, C1-4 mono and di-alkyl amino;
• and
• p is 0, 1 or 2;
• or a pharmaceutically acceptable salt or solvate thereof, including all stereoisomers and tautomers thereof.